natgillin/translations-raw huggingface dataset:
A method of imaging one or more cells, organs or tissues comprising exposing the cell to or administering to a organism an effective amount of a compound according to claim 12 . 
Tvar u skladu s bilo kojim od patentnih zahtjeva 12-14 za uporabu u slikovnoj metodi za jednu ili više stanica, organa ili tkiva.
The polymer conjugate of any of claims 1 to 9 and 12 wherein the biologically active fragments of the Anopheles gambia wild type HMGB1 Box-A is a fragment of at least 77 or at least 54 amino acids respectively and comprises the amino acid sequences as defined in SEQ ID NO:419 or 529 respectively and wherein the polypeptide variant of said biologically active fragments of the Anopheles gambia HMGB1 Box-A is selected from the group consisting of the amino acid sequences as defined in any of SEQ ID NO:420 to 528 or 530 to 610. 
Polimerni konjugat iz bilo kojeg od zahtjeva 1 do 9 i 12, naznačen time, što je biološki aktivni fragment divljeg tipa HMGBI Box-A Anopheles gambia fragment od bar 77 ili bar 54 amino-kiseline, respektivno, i sadrži aminokiselinske sekvence kako je definirano u SEQ ID NO: 419 ili 529, respektivno i gdje je polipeptidna varijanta spomenutih biološki aktivnih fragmenata Anopheles gambia HMGBI Box-A odabrana iz grupe koja se sastoji od aminokiselinskih sekvenci kako je definirano u bilo kojoj od SEQ ID NO: 420 do 528 ili 530 do 610.
A process according to claim 12, wherein the amine salt NHR3R4.HCl used in step (b) is recrystallised from methanol/diethyl ether prior to use. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se aminsku sol NHR/R*HCI, upotrijebljenu u koraku (b), prije upotrebe prekristalizira iz smjese metanol/dietil-eter.
The combination as defined in Claim 4 wherein the antidiabetic agent is at least one agent selected from the group consisting of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR gamma agonist, a PPAR alpha/gamma dual agonist, an aP2 inhibitor, a DPP4 inhibitor, an insulin sensitizer, a glucagon-like peptide-1 (GLP-I), a PTP1B inhibitor, a glycogen phosphorylase inhibitor, a glucos-6-phosphatase inhibitor, insulin and a meglitinide. 
Kombinacija prema patentnom zahtjevu 4, naznačena time što je antidijabetično sredstvo najmanje jedno sredstvo izabrano iz grupe koju čine biguanid, sulfonil urea, inhibitor glukozidaze, PPAR gama agonist, PPAR alfa/gama dvostruki agonist, aP2 inhibitor, DPP4 inhibitor, sredstvo koje povećava osjetljivost na inzulin, glukagonu-sličan peptid-1 (GLP-I), PTPIB inhibitor, inhibitor glikogen fosforilaze, inhibitor glukozo-6-fosfataze, inzulin 1 meglitinid.
The vinylamide polymer concentration can be less than about 4 weight % of the total reaction mixture, and the vinylamide polymer can have an average molecular weight of about 30,000 to about 1,000,000 Daltons. 
(a) manje od 4%, težinski, od ukupne reakcijske smjese, te ima prosječnu molekulsku težinu od 50.000 do 1.000.000 Da; i
The roll of any of the preceding claims, wherein the C content in the steel composition is between 0.85 - 0.9 % C in terms of % per weight of total roll weight. 
Valjak prema prethodnim zahtjevima, pri čemu sadržaj C u sastavu čelika iznosi između 0,85-0,9 % C u postotnoj težini ukupne težine valjka.
The composite material may comprise other constituents which provide beneficial rheological, cosmetic, etc. properties. 
Kompozitni materijal može sadržavati sastojke koji daju dobra reološka, kozmetička itd. svojstva.
The vaccine according to claim 16, wherein one of the hydroxyl-groups of the carbohydrate is substituted with the sulphate group, and wherein substantially all of the remaining hydroxyl-groups of the carbohydrate are substituted with fatty acids. 
Adjuvant sukladno bilo kojem od zahtjeva 4 - 8, naznačen time što je jedna od hidroksilnih skupina ugljikohidrata supstituirana sulfatnom skupinom, i gdje su u osnovi sve preostale hidroksilne skupine ugljikohidrata supstituirane masnim kiselinama.
A pharmaceutical composition according to clause 1, is a once-daily dosage form comprising 600mg of rifaximin. A pharmaceutical composition as in clause 1 is administered to increase patient compliance for treatment of traveler's diarrhea, hepatic encephalopathy, infectious diarrhea, diverticular disease, an antibacterial prophylactic prior to colon surgery, irritable bowel syndrome, Crohn's disease, Clostridum difficile-associated diarrhea, small intestinal bacterial overgrowth, traveler's diarrhea prophylaxis, dysentery, pouchitis, peptic ulcer disease, surgical prophylaxis and gastric dyspepsia. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da služi za povećanje spremnosti pacijenta za liječenje putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnih proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu i za liječenje želučane dispepsije.
Preferably the disease or disorder is a tumor-related disease and in particular embodiments is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 naznačeno time, što bolest ili poremećaj je bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz skupine koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma pankreasa, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave-vrata, karcinoma žučne vrećice i njihovih metastaza.
The method according to claim 14, characterized in that said filler material (3) is constituted by waste of industrial processes. 
Postupak prema zahtjevu 14, naznačen time, da je spomenuti materijal punila (3) sastavljen od otpadaka nakon industrijskih procesa, t>& (n
A CAR according to any one of paras 1 to 3 wherein the spacer comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or a sequence at least 90% identical thereto. 
Kimerni antigenski receptor (CAR) koji sadrži izvanstaničnu razmaknicu naznačen time što razmaknica sadrži sekvencu odabranu iz skupine koju čine SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 ili SEQ ID NO:7 ili sekvencu koja je ovima najmanje 90% identična.
wherein X is a OH or a leaving group, to form a compound of formula (XXII): 
SN Nj KA O gdje, X je OH ili odlazeća grupa, da bi se formirao spoj formule (XXIII):
and Y are each independently a group containing a first functional group (FG1), the FG1 being selected from the group consisting of: acetylene, azide, aldehyde, hydroxylamine, hydrazine, ketone, nitrobenzofurazan (NBD), dansyl, fluorescein, biotin, and Rhodamin, 
(I) pri čemu su P, i Y svaki nezavisno skupina koja sadržava prvu funkcionalnu skupinu (FG1), FG1 je odabran iz skupine koju čine: acetilen, azid, aldehid, hidroksilamin, hidrazin, keton, nitrobenzofurazan (NBD), danzil, fluorescein, biotin i Rodamin,
A multicomponent microbicidal contraceptive intravaginal ringed-mesh device as in claim 11 wherein the at least one other bioactive agent is selected from the group consisting of metronidazole, miconazole, ketoconazole, fluconazole, tobramycin, rapamycin, amphotericin, 5-flurocystine, clotrimazole, mafenide, a chlorhexidine salt, tetracycline, neomycin, mitomycin, gemcitabine, gentamicin, and clindamycin. 
Uređaj u vidu višekomponentne mikrobicidne kontraceptivne intravaginalne prstenaste mrežice u skladu s patentnim zahtjevom 9, naznačen time što se najmanje jedno drugo bioaktivno sredstvo bira iz skupine koju čine metronidazol, mikonazol, ketokonazol, flukonazol, tobramicin, rapamicin, amfotericin, 5-fluorcitozin, klotrimazol, mafenid, sol klorheksidina, tetraciklin, neomicin, mitomicin, gemcitabin, gentamicin, te klindamicin.
The liquid oral preparations can be in the form of, for example, aqueous or oily suspensions or solutions, emulsions, syrups, or can be presented as dry product for reconstitution with water or other suitable carrier before use. 
Tekući oralni pripravci mogu biti primjerice u obliku vodenih ili uljnih suspenzija ili otopina, emulzija, sirupa ili mogu biti prisutni u suhom produktu kojem valja dodati vodu ili neki pogodni nosač prije upotrcbc.
a cell coverage component (LBAS GT) with information about geographical area where the alert messages are to be sent, 
- < komponentom pokrivanja stanice, LBAS GT (40), s informacijom o zemljopisnom području gdje se trebaju slati poruke upozorenja,
In yet another embodiment of this invention there is disclosed the compound of formula (I), wherein R4 and R5 taken together with the nitrogen atom to which they are attached form piperidine, piperazine or morpholine, which are optionally substituted one or more times with methyl, ethyl, phenyl or acetyl. 
R,1i Rs, uzeti zajedno s atomom dušika na kojeg su vezani, tvore piperidin, piperazin ili morfolin, izborno jednom ili višestruko supstituirane s metilom, etilom, fenilom ili acetilom; ili
is CHF2, CF3, H, F, Cl, —CN, or R1 and R2 may be taken together with their attached ring A to form a fused ring system selected from the group consisting of naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, and quinolinyl, wherein said naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, and quinolinyl are optionally substituted with F, CHF2, CH2F, CF3, or CH3; provided that R2 may not be H if R1 is H; 
R' je H, Cl, OCFa, Ca-syalkil, -CN, F, OCa. alkil, OCHF-, ili cikloprspil, pri čemu je navedeni Cqoalkil 25 proizvoljno supstituiran s do pet fluorovih atoma; Rčje CHF,, CF,, H, F, Cl, -CN, ili R'i R* mogu biti uzeti zajedno s prstenom A za koji su vezani da tvore spojeni prstenasti sustav odabran iz skupine koju čine naftalenil, izokinolinil, tetrahidronaftalenil, i kinolinil, pri čemu su navedeni naftalenil, 30
A process for the manufacture of a compound of the Formula IIa: wherein R is a suitable sulphonate ester; 
Postupak za proizvodnju 7-hidroksi-4-(4-bromo-2-fluoroanilino)-6-metoksikinazolina, spoja sa formulom IX:
Of particular note are additional biologically active compounds or agents selected from insecticides of the group consisting of sodium channel modulators, cholinesterase inhibitors, neonicotinoids, insecticidal macrocyclic lactones, GABA-regulated chloride channel blockers, chitin synthesis inhibitors, juvenile hormone mimics, octopamine receptor ligands, ecdysone agonists, ryanodine receptor ligands, nereistoxin analogs, mitochondrial electron transport inhibitors, lipid biosynthesis inhibitors, cyclodiene insecticides, nucleopolyhedrovirus; a member of Bacillus thuringiensis, an encapsulated delta-endotoxin of Bacillus thuringiensis; and a naturally occurring or a genetically modified viral insecticide. 
Smjesa iz Zahtjeva 10, naznačena time, što se bar jedno dodatni biološki aktivni spoj ili sredstvo bira od insekticida iz grupe koja se sastoji od modulatora natrijevih kanala, inhibitora holinesteraze, neonikotinoida, insekticidnih makrocikličnih laktona, blokatora GABA-reguliranih kloridnih kanala, inhibitora sinteze hitina, mimetika juvenilnog hormona, liganada receptora za oktopamin, agonista ekdizona, liganada rijanoidnog receptora, analoga nereistoksina, inhibitora transporta elektrona u mitohondrijima, inhibitora biosinteze lipida, ciklodienskih HR P20110223 TI insekticida, inhibitora presvlačenja, nukleopoliedrovirusa, člana Bacillus thuringiensis, inkapsuliranog delta- endotoksina Bacillus thuringiensis i prirodnog ili genetički modificiranog virusnog insekticida.
a stoma seal support is coupled to the second wall for supporting the stoma seal (22) at the first aperture (16), the stoma seal support further comprising a second coupling element (34). 
(d) nosač stoma brtve je spojen na drugi zid za podupiranje stoma brtve (22) na prvi otvor (16), nosač stoma brtve nadalje sadrži drugi element za spajanje (34).
As shown in Figure 2B, the container 101 is inverted and may rest on the cap 200. 
Kako je prikazano na Slici 2B, posuda 101 je okrenuta i može stajati na poklopcu 200.
is hydrogen or fluoro; is hydrogen or methyl; and 
R* je vodik ili metil; i R je vodik ili fluoro.
Method according to claim 2, wherein pickling is made by spraying the strip with an aqueous solution of 5 to 30 g/l, preferably 8 to 15 g/l, of a first initial solution comprising 25 to 50 wt.-% sulphuric acid and 5 to 15 wt.-% non ionic tenside, and 0.1 to 10 g/l, preferably 1 to 3 g/l, of a second initial solution comprising 5 to 7 wt.-% hydrofluoric acid. 
Postupak prema zahtjevu 2, naznačen time, da se luženje vrši putem sprejanja trake s vodenom otopinom od 5 do 30 g/l, poželjno od 8 do 15 g/l prve početne otopine koja sadrži od 25 do 50 masenih % sumporne kiseline i od 5 do 15 masenih % ne-ionskog tenzida, te od 0,1 do 10 g/l, poželjno od 1 do 3 g/l druge početne otopine koja sadrži od 5 do 7 masenih % fluorovodične kiseline.
The LC conditions (Symmetry C18 column 4.6×30 mm with a particle size of 3.5 gm) were linear gradient elution with eluents A (water containing 0.05% TFA) and B (acetonitrile containing 5% water and 0.035% TFA). 
LC uvjeti(Symmetry C18 stup 4,6x30 mm s česticom veličine 3.5 um) su bili elucija linearnog gradijenta s eluentima A (voda koja sadrži 0,05 %. TFA) i B (acetonitril koji sadrži 5% vode i 0,035 % TFA).
L is selected from q ranges from 1 to 4, and Ab is an antibody or a fragment or derivative thereof. 
E O q je u rasponu od 1 do 4, a Ab je protutijelo ili njegov fragment ili derivat.
The composition as defined in claim 2 or 3, wherein the glutamate residue present at the N terminus of the polypeptides of HDM201 ESVKYVQSNGGAI and/or HDM03W ELVDSASQHG is replaced with pyroglutamate. 
Sastav kao što je definirano u zahtjevu 2 ili 3, naznačen time, što je ostatak glutamata prisutan na N kraju polipeptida od HDM201 ESVKYVQSNGGAJ i / ili HDM03W ELVDSASQHG zamijenjen sa piroglutamatom.
The method of claim 6, wherein the extraction of the cholesterol is carried out with a non-water-miscible solvent. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se ekstrakciju kolesterola provodi otapalom koje se ne miješa s vodom.
According to the invention, comminution is taken to mean pulverisation of the dosage form with conventional means which are available to an abuser, such as for example a mortar and pestle, a hammer, a mallet or other usual means for pulverisation by application of force. 
Pod usitnjavanjem se prema izumu podrazumijeva pulveriziranje oblika davanja uobičajenim sredstvima, koja zlorabitelju uobičajeno stoje na raspolaganju, kao na pr. mužar i tučak, čekić, batić ili druga uobičajena sredstva za pulveriziranje pod djelovanjem sile. HR P20070272 T3
The antibody according to any one of the preceding claims, wherein the antibody comprises human light chain and human heavy chain variable regions, wherein the light chain variable region comprises a VL CDR1 having the sequence as set forth in SEQ ID No:23, a VL CDR2 having the sequence as set forth in SEQ ID No:24 and a VL CDR3 having the sequence as set forth in SEQ ID No:25, and the heavy chain variable region comprises a VH CDR1 having the sequence as set forth in SEQ ID No:28, a VH CDR2 having the sequence as set forth in SEQ ID No:29 and a VH CDR3 having the sequence as set forth in SEQ ID No:30. 
Monoklonsko protutijelo koje se vezuje za humani CD38, pri čemu navedeno protutijelo sadrži humani laki lanac i varijabilne regije humanog teškog lanca, pri čemu varijabilna regija lakog lanca sadrži VL CDR1 koji ima slijed naveden u SEQ ID No: 13, VL CDR2 koji ima slijed naveden u SEQ ID br: 14 i VL CDR3 koji ima slijed naveden u SEQ ID br: 15, a varijabilno područje teškog lanca sadrži VH CDR1 koji ima slijed kao što je navedeno u SEQ ID br: 18, VH CDR2 koji ima slijed naveden u SEQ ID br:19 i VH CDR3 koji ima slijed kako je navedeno u SEQ ID br:20.
The use of any of claims 28 to 34, wherein the medicament is an aerosol produced with a vibrating mesh nebulizer, preferably a PARI E-FLOW® nebulizer. 
Uporaba iz bilo kojeg patentnog zahtjeva 28 do 34, pri čemu je lijek aerosol proizveden s nebulizatorom s vibrirajućom mrežicom, preporučljivo PARI E-FLOW& nebulizator.
The present invention is directed to nucleic acids encoding the elastase proteins of the invention. Thus, in certain embodiments, the present invention provides a nucleic acid molecule comprising a nucleotide sequence which encodes a proelastase protein (including but not limited to a protein of any one of SEQ ID NOS:6-9, 64-69, 88-91, or 98-103) comprising (i) an activation sequence comprising an elastase recognition sequence operably linked to (ii) the amino acid sequence of a protein having type I elastase activity. 
PATENTNI ZAHTJEVI Autoaktivacijski protein proelastaze koji sadrži (1) sekvencu propeptida koja sadrži aktivacijsku peptidnu sekvencu elastaze koja sadrži aminokiseline označene P10-P9-P8-P7-P6-P5-P4-P3-P2-P1, od kojih su aminokiseline P3-P2- P1 napravljene da formiraju sekvencu prepoznavanja elastaze, operativno povezanu na (ii) aminokiselinsku sekvencu zrelog tipa I elastaze čije su tri N-terminalne aminokiseline označene P1'- P2'- P3', naznačen time da (a) sekvenca propeptida nije porijeklom iz zrelog tipa I elastaze, i
The medical device of claim 19, wherein the medical device is selected from the group consisting of stents, grafts, and implants. 
Medicinsko sredstvo prema zahtjevu 19, naznačeno time da je navedeno medicinsko sredstvo izabrano iz grupe koju čine stentovi, transplantati i implantati.
The process of claim 14 wherein the inert organic non-solvent is selected from lower aliphatic hydrocarbons and the inert organic solvent is selected from aromatic hydrocarbons. 
Postupak kao što je u patentnom zahtjevu 20, naznačeno time da je inertno organsko ne-otapalo odabrano od nižih alifatskih ugljikovodika, a inertno organsko otapalo odabrano je od aromatskih ugljikovodika.
In some embodiments, a composition of the invention includes a hybrid nuclease molecule comprising a human RNase and a mutant human IgG1 Fc domain, wherein the human RNase is operatively coupled to the Fc domain and wherein the Fc domain includes a P238S mutation and a P331S mutation and has reduced cytotoxicity relative to a hybrid nuclease molecule having an unmodified Fc domain, and wherein the hybrid nuclease molecule comprises an amino acid sequence set forth in SEQ ID NO: 96, 92, 62, or 78; or an amino acid sequence set forth in SEQ ID NO: 98 or 94. 
HR P20180564 T1 PATENTNI ZAHTJEVI Molekula hibridne nukleaze koja sadrži ljudsku RNazu i mutant ljudske IgGI Fc domene, pri čemu je ljudska RNaza operativno vezana na Fc domenu i pri čemu Fc domena uključuje mutaciju P238S 1 mutaciju P331S i ima smanjenu citotoksičnost u odnosu na hibridnu molekulu nukleaze koja ima nemodificiranu Fc domenu, te pri čemu molekula hibridne nukleaze sadrži: sekvencu aminokiseline navedenu u SEQ ID NO: 96, 92, 62 ili 78; ili sekvencu aminokiseline navedenu u SEQ ID NO: 98 ili 94.
The container according to any of the preceding claims, wherein the pharmaceutical composition is a liquid HSA-free formulation comprising 30 to 100 µg/ml of interferon-B, an isotonicity agent, 0.1 to 2 mg/ml of a surfactant, at least 0.12 mg/ml of an antioxidant and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0. 
Spremnik prema bilo kojem od prethodnih zahtjeva, naznačen time da farmaceutski pripravak je tekuća formulacija bez-HSA koja sadrži 30 do 100 ug/ml interferona-B, izotonično sredstvo, 0.1 do 2 mg/ml surfaktanta, barem 0.12 mg/ml antioksidanta i pufersku otopinu koja je sposobna održavati pH tekuće formulacije na vrijednosti između 3.0 i 4.0.
“*” means a chiral center with absolute stereochemistry (R) or (S), comprising treating a chiral compound of formula (II), 
"*" znači kiralni centar s apsolutnom stereokemijom (R) ili (S), naznačen time, da se sastoji od obrade spoja formule (II),
A compound of any one of claims 1-5 for use as a medicament for treating a subject having neuronal cells with an over accumulation of iron. 
Spoj u skladu s patentnim zahtjevom 1, namijenjen upotrebi kao medikament za liječenje stanica ili tkiva uključenog u patologiju, naznačen time što postoji abnormalna funkcija neurona kod subjekta.
Two sites partially occupied with water molecules are localized in the asymmetric unit (also containing two principle molecules). 
Dva mjesta djelomično zauzeta vodom su lokalizirana u asimetričnoj ćeliji (također sadrži i dvije glavne molekule).
The method of claim 7, wherein the first waste stream is heated to a temperature of at least 290 °C. 
temperatura kombiniranog prvo toka otpada je povećana na najmanje 350 °C;
A control system of an electric motor for surgical applications comprising a console, an electric micromotor, an intelligent tray and a pedal, said console comprising an 
HR P20100055 TI PATENTNI ZAHTJEVI Upravljački sustav elektromotora za kirurške primjene koji sadržava konzolu, električni mikro motor, inteligentni držač i pedalu, pri čemu konzola sadržava
Use of a kit according to any of claims 6 to 8, wherein said reagent includes those of a Biorad or R and D Luminex Kit. 
Pokus u skladu s patentnim zahtjevom 9, naznačen time, da se u postupku Luminex koristi Biorad ili R i D Luminex Kit.
The vaccine of claim 3, wherein the antigen is of bacterial origin, viral origin or parasitic origin. 
Cjepivo u skladu s patentnim zahtjevom 2, naznačeno time što je antigen bakterijskog podrijetla, virusnog podrijetla ili parazitnog poidrijetla.
an antibody light chain comprising an antibody light chain sequence of SEQ ID NO: x+1 or a variant thereof; 
(11) lakog lanca čija sekvenca odgovara sekvenci lakog lanca antitijela izabranoj iz grupe koju čine SEQ ID NO:
Purification of the crude by chromatography on silica eluting with iso-hexane/ethyl acetate (3:1 increasing to 2:1) yields the titled product. (MH+ 455) 
Čišćenjem sirovog proizvoda kromatografijom na silika gelu ispirući s izo-heksan/etil acetatom (3:1 rastući do 2:1) dobije se naslovni proizvod.
A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, for use in treating an inflammatory disorder selected from the group consisting of asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, pain, and arthritis including rhematoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis. 
Uporaba spoja prema zahtjevu 10, naznačena time što se radi o upalnom poremećaju iz skupine koja obuhvaća astmu, sindrom respiratornog distresa kod odraslih, kroničnu opstruktivneu plućnu bolest, kroničnu plućnu inflamatornu bolest, dijabetes, upalnu bolest crijeva, osteoporozu, psorijazu, odbacivanja transplantanta, aterosklerozu, bol i artritis, uključujući reumatoidni artritis, psorijatični artritis, traumatski artritis, rubella artritis, giht i osteoartritis
A compound of Formula (I) according to claims 1 or 2 wherein both R1 and R2 are hydrogen or one is hydrogen and the other is methyl or trifluoromethyl. 
Spoj formule (I) prema patentnim zahtjevima 1 ili 2 naznačeno time da oba R1 i R2jesu vodik ili jedan jest vodik a drugi je metil, etil, propil, fert-butil, koji može biti supstituiran s hidroksi ili fluorom, C3-C6 cikloalkil, koji može biti supstituiran s hidroksi ili fluorom.